Third quarter biopharmaceutical start-up financings fell 23% from the second quarter, but large individual company financings continue to stand out, including Century Therapeutics with a $250m series A venture capital round and a $121m series B for Achilles Therapeutics Ltd. Four start-ups went public in the third quarter, including the Pfizer Inc. spin-out SpringWorks Therapeutics Inc. with the largest initial public offering totaling $173.3m.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?